Vanda Pharmaceuticals Inc (NASDAQ:VNDA): 10.02 million shares exchanged hands on Friday

699

Dallas, Texas 11/18/2013 (Financialstrend) – In Friday’s trading session, Vanda Pharmaceuticals Inc (NASDAQ:VNDA) rose by 11.86 %. The shares opened at a price of $15.29, which touched the intraday high of $15.64 and headed to a close of $14.59. Around 10.02 million exchanged hands over the trading day and an average volume of 2.30 million shares were traded over a 30 day period. The 52-week low of Vanda Pharmaceuticals Inc (NASDAQ:VNDA) shares is $2.99 and its 52-week high is $15.65. The company has a market capitalization of $415.46 million.                                        

About the company

Vanda Pharmaceuticals Inc (NASDAQ:VNDA) was incorporated on 13 November, 2002 and  is a bio-pharmaceutical company. It is focused on developing & commercializing products that are used or the treatment of various central-nervous system disorders. Vanda Pharmaceuticals Inc (NASDAQ:VNDA)’s product-portfolio includes tasimelteon. This  is a compound that is used the treatment of circadian-rhythm sleep disorders.

It is in clinical-development for Non-24. In addition to this the company also manufactures Fanapt. This is a compound that is used to treat schizophrenia. It is an oral-formulation that is marketed & sold in the U.S. by Novartis Pharma & VLY-686, which is a small-molecule-neurokinin-1 receptor (NK-1R) antagonist.

Tasimelteon

Tasimelteon is a circadian-regulator that is in development for treatment of Non-24. It  is a melatonin-agonist of the human MT1 & MT2 receptors, with a greater-specificity for MT2. Tasimelteon’s has the ability to reset the master-body clock in the suprachiasmatic-nucleus. This is  situated in the hypothalamus. This results in  entrainment of the body’s melatonin & cortisol rhythms to align itself to the 24-hour day-night-cycle. Tasimelteon was also indicated to significantly- improve clinical symptoms in numerous sleep & wake measures.

 Fanapt

Fanapt is the compound that is used in the treatment of schizophrenia. Novartis has the exclusive commercialization-rights to all the Fanapt formulations in the United States & Canada.

Subscribe to get your free report!

* indicates required
*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.